Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Annals of the Rheumatic Diseases · 2026-09 · 85 (9) · 1879-1889
DOI: 10.1016/j.ard.2026.02.017 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-09. Verfasst von Deanna P Jannat-Khah und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; Division of Rheumatology, Department of Medicine, …. Hauptthemen laut MEDLINE: Glucocorticoids, Immune Checkpoint Inhibitors, Arthritis, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, University Hospitals of the Great West Health Cooperation Group.
Abstract (Originalsprache)
OBJECTIVES: Glucocorticoids are the first-line treatment for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA). However, glucocorticoids may negatively impact cancer progression-free survival (PFS). We investigated the association between glucocorticoids and PFS among patients with cancer with ICI-IA. METHODS: Data from the prospective multicentre rheumatic adverse events due to Immunotherapy Observational Study registry were used. Kaplan-Meier plots and multivariable Cox regression models (time-varying and landmark) assessed glucocorticoid dose and its association with PFS. Participants who progressed before glucocorticoid initiation were excluded from the landmark analysis. RESULTS: Participants with ICI-IA (N = 269) had a mean age of 64.85 years (SD: 12.87), 48.3% were female, 87% were White, 32% had melanoma, and most were stage IV (56.4%). In the first month of treatment, the median glucocorticoid dose (prednisone equivalent) was 13 mg daily and 7.8% of participants received an immunomodulatory disease-modifying antirheumatic drug. Cancer progression occurred in 67 participants (24.9%). In a time-varying Cox model, glucocorticoids were not associated with PFS (adjusted hazard ratio [aHR]: 2.64 [95% CI: 0.36-19.61]). Glucocorticoid doses above the median compared with below the median in the first month of ICI-IA treatment were not associated with worse PFS in adjusted Cox models (aHR: 1.15 [95% CI: 0.59-2.25]). CONCLUSIONS: In this prospective ICI-IA cohort, low doses of glucocorticoids (median dose 13 mg [IQR: 7.5, 25] in the first month of treatment) did not adversely affect PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA; Division of Rheumatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. Electronic address: jannatk…
- Department of Medicine, Section of Rheumatology, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA.
- Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- MD Anderson Cancer Center, Section of Rheumatology & Clinical Immunology, University of Texas, Houston, TX, USA.
- Department of Rheumatology & Rehabilitation, Assiut University Faculty of Medicine, Assiut, Egypt; Department of Cancer Sciences, Global Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, OH, USA;…
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Förderung
- NIAID NIH HHS
- NIAMS NIH HHS
- University Hospitals of the Great West Health Cooperation Group
- Hospital for Special Surgery
- Philippe Foundation Inc
- Société Française de Rhumatologie
- Johns Hopkins University
- National Institutes of Health
Zitieren
APA
Jannat-Khah, D. P., Reid, P., Cappelli, L. C., Suarez-Almazor, M. E., Abdel-Wahab, N., Sparks, J. A., Braaten, T. J., Meara, A., Nong, M., Ge, K., Katsumoto, T. R., Calabrese, C., Tison, A., Chan, K., Ghosh, N., Shah, A. A., Bingham, C., & Bass, A. R. (2026). Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Annals of the Rheumatic Diseases, 85(9), 1879-1889. https://doi.org/10.1016/j.ard.2026.02.017
Vancouver
Jannat-Khah DP, Reid P, Cappelli LC, Suarez-Almazor ME, Abdel-Wahab N, Sparks JA, et al. Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Annals of the Rheumatic Diseases. 2026;85(9):1879-1889. doi:10.1016/j.ard.2026.02.017
BibTeX
@article{JannatKhah2026,
author = {Jannat-Khah, Deanna P and Reid, Pankti and Cappelli, Laura C and Suarez-Almazor, Maria E and Abdel-Wahab, Noha and Sparks, Jeffrey A and Braaten, Tawnie J and Meara, Alexa and Nong, Minerva and Ge, Kyle and Katsumoto, Tamiko R and Calabrese, Cassandra and Tison, Alice and Chan, Karmela and Ghosh, Nilasha and Shah, Ami A and Bingham, Clifton and Bass, Anne R},
title = {Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {9},
pages = {1879--1889},
doi = {10.1016/j.ard.2026.02.017}
}
EUVIMED